GC Biopharma Corp. (KRX:006280)
South Korea flag South Korea · Delayed Price · Currency is KRW
167,700
-900 (-0.53%)
Feb 26, 2026, 12:30 PM KST

GC Biopharma Balance Sheet

Millions KRW. Fiscal year is Jan - Dec.
Fiscal Year
TTMFY 2024FY 2023FY 2022FY 2021FY 2020
Period Ending
Sep '25 Dec '24 Dec '23 Dec '22 Dec '21 Dec '20
Cash & Equivalents
64,08522,56349,706105,366186,060232,288
Short-Term Investments
-000-0--
Trading Asset Securities
4,4321,4325,8006,94016,87523,210
Cash & Short-Term Investments
68,51723,99555,506112,306202,935255,498
Cash Growth
46.82%-56.77%-50.58%-44.66%-20.57%80.53%
Accounts Receivable
541,325386,526436,957394,155413,817402,088
Other Receivables
7,1829,63511,97613,7789,62420,598
Receivables
549,906404,812450,933409,433423,987422,736
Inventory
849,437746,582516,245442,408454,976437,071
Prepaid Expenses
12,9839,6384,1474,1573,2759,513
Other Current Assets
13,64416,80612,31612,1335,3467,223
Total Current Assets
1,494,4871,201,8331,039,148980,4371,090,5191,132,042
Property, Plant & Equipment
952,766915,826952,703930,822899,847751,099
Long-Term Investments
206,258225,340206,646216,273110,96292,030
Goodwill
-125,614142,475142,475142,47510,065
Other Intangible Assets
438,33872,53586,16676,73557,24031,797
Long-Term Accounts Receivable
210-----
Long-Term Deferred Tax Assets
61,16949,94135,18527,83919,83220,686
Long-Term Deferred Charges
-109,236109,24092,35377,69167,702
Other Long-Term Assets
38,02043,27268,97253,82463,29945,700
Total Assets
3,191,5282,743,8762,643,3142,525,5372,462,1452,151,400
Accounts Payable
248,804156,818143,816121,270119,541134,785
Accrued Expenses
68,10140,07334,000102,06685,78182,684
Short-Term Debt
411,162367,092315,447182,000104,836203,200
Current Portion of Long-Term Debt
255,06610,829202,8135,416120,53991,175
Current Portion of Leases
15,43414,30414,33511,5809,8877,505
Current Income Taxes Payable
11,5057,8732,04117,15828,33811,663
Current Unearned Revenue
5242,0251,6297,0847,730582
Other Current Liabilities
260,278170,461154,83594,16576,23157,810
Total Current Liabilities
1,270,873769,475868,917540,738552,883589,403
Long-Term Debt
232,805339,50684,891278,797280,343194,160
Long-Term Leases
108,45096,412106,53697,75190,96970,392
Long-Term Unearned Revenue
7,2957,4007,50014,04916,2965,606
Pension & Post-Retirement Benefits
38,31116,8051,3561,1711,4975,711
Long-Term Deferred Tax Liabilities
12,9854,0632,2131,3581,8691,876
Other Long-Term Liabilities
31,33129,20032,03825,03118,53114,946
Total Liabilities
1,702,0491,262,8601,103,451958,895962,388882,094
Common Stock
58,43358,43358,43358,43358,43358,433
Additional Paid-In Capital
396,224396,220393,605393,531385,821337,016
Retained Earnings
881,845815,336872,989903,467867,353757,278
Treasury Stock
-35,702-35,702-35,702-35,702-35,702-35,702
Comprehensive Income & Other
-1,48418,35810,9128,394-1,1341,498
Total Common Equity
1,299,3171,252,6451,300,2361,328,1221,274,7711,118,524
Minority Interest
190,162228,371239,627238,520224,987150,782
Shareholders' Equity
1,489,4791,481,0161,539,8631,566,6421,499,7571,269,306
Total Liabilities & Equity
3,191,5282,743,8762,643,3142,525,5372,462,1452,151,400
Total Debt
1,022,917828,142724,022575,543606,574566,432
Net Cash (Debt)
-954,400-804,147-668,516-463,238-403,639-310,934
Net Cash Per Share
-83622.65-70457.79-58574.02-40587.96-35366.01-27243.38
Filing Date Shares Outstanding
11.4111.4111.4111.4111.4111.41
Total Common Shares Outstanding
11.4111.4111.4111.4111.4111.41
Working Capital
223,614432,358170,231439,698537,637542,639
Book Value Per Share
113843.54109754.26113924.12116367.45111692.8698002.82
Tangible Book Value
860,9791,054,4961,071,5951,108,9121,075,0561,076,662
Tangible Book Value Per Share
75437.2692392.8293891.0597160.6994194.2494334.96
Land
-17,50917,34617,38318,02517,976
Buildings
-705,071695,794638,353572,756508,734
Machinery
-430,546407,055369,503333,326310,115
Construction In Progress
-43,02859,224103,334150,17685,095
Source: S&P Global Market Intelligence. Standard template. Financial Sources.